All In Biotech

Drug Trial Radar · NCT04774926

Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.

One Year, Single Arm, Open Label, Multicenter, Phase IV Study Using Multimodal Imaging to Guide Disease Activity Assessment Through Innovative Early Predictive Anatomical Biomarkers of Fluid Resolution in wAMD Patients Treated With Brolucizumab- IMAGINE Study

Last checked: Nov 20, 2026Latest source record: May 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

122

Actual

Start

Oct 15, 2021

Primary completion

Oct 4, 2023

Study completion Oct 4, 2023

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to identify innovative early imaging parameters as predictors of the long-term clinical response to brolucizumab in terms of fluid resolution in patients with wet Age-related Macular Degeneration (wAMD) to evaluate their potential in supporting the choice of treatment regimen (q12w or q8w).

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

  • BrolucizumabDrug

    120 mg/ml solution for intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients Classified as q12w Fluid-free or Not q12w Fluid-freeTime frame: Up to Week 48
  2. Potential Predictor Factors of Fluid-free Response: Type of Predominant Basal Choroidal Neovascularization (CNV) Lesion Type, as Assessed by SD-OCT at Baseline - Patients Classified as Not q12w Fluid-freeTime frame: Baseline
  3. Potential Predictor Factors of Fluid-free Response: Type of Predominant Basal Choroidal Neovascularization (CNV) Lesion Type, as Assessed by SD-OCT at Baseline - Patients Classified as q12w Fluid-freeTime frame: Baseline
  4. Potential Predictor Factors of Fluid-free Response: Sub-retinal Pigment Epithelium (Sub-RPE) Fluid - Patients Classified as Not q12w Fluid-freeTime frame: Baseline to Week 16
  5. Potential Predictor Factors of Fluid-free Response: Sub-retinal Pigment Epithelium (Sub-RPE) Fluid - Patients Classified as q12w Fluid-freeTime frame: Baseline to Week 16
  6. Potential Predictor Factors of Fluid-free Response: Subretinal Hyperreflective Material (SHRM) - Patients Classified as Not q12w Fluid-freeTime frame: Baseline to Week 16
  7. Potential Predictor Factors of Fluid-free Response: Subretinal Hyperreflective Material (SHRM) - Patients Classified as q12w Fluid-freeTime frame: Baseline to Week 16
  8. Potential Predictor Factors of Fluid-free Response: Outer Retinal Tubulation (ORT) - Patients Classified as Not q12w Fluid-freeTime frame: Baseline to Week 16
  9. Potential Predictor Factors of Fluid-free Response: Outer Retinal Tubulation (ORT) - Patients Classified as q12w Fluid-freeTime frame: Baseline to Week 16
  10. Potential Predictor Factors of Fluid-free Response: External Limiting Membrane (ELM) Integrity Loss in Center 1 mm - Patients Classified as Not q12w Fluid-freeTime frame: Baseline to Week 16
  11. Potential Predictor Factors of Fluid-free Response: External Limiting Membrane (ELM) Integrity Loss in Center 1 mm - Patients Classified as q12w Fluid-freeTime frame: Baseline to Week 16
  12. Potential Predictor Factors of Fluid-free Response: Type of Pigment Epithelium Detachment (PED) - Patients Classified as Not q12w Fluid-freeTime frame: Baseline to Week 16
  13. Potential Predictor Factors of Fluid-free Response: Type of Pigment Epithelium Detachment (PED) - Patients Classified as q12w Fluid-freeTime frame: Baseline to Week 16
  14. Potential Predictor Factors of Fluid-free Response: Percentage Changes in Central Subfield Thickness (CST) From Baseline at Week 16 - Patients Classified as q12w Fluid-freeTime frame: Baseline, Week 16
  15. Potential Predictor Factors of Fluid-free Response: Percentage Changes in Central Subfield Thickness (CST) From Baseline at Week 16 - Patients Classified as Not q12w Fluid-freeTime frame: Baseline, Week 16

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Naples, Italy

  • Novartis Investigative Site

    Naples, Italy

  • Novartis Investigative Site

    Ancona, AN, Italy

  • Novartis Investigative Site

    Acquaviva delle Fonti, BA, Italy

  • Novartis Investigative Site

    Bologna, BO, Italy

  • Novartis Investigative Site

    Cagliari, CA, Italy

  • Novartis Investigative Site

    Florence, FI, Italy

  • Novartis Investigative Site

    Monza, MB, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Padova, PD, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Siena, SI, Italy

  • Novartis Investigative Site

    Torino, TO, Italy

  • Novartis Investigative Site

    Trieste, TS, Italy

  • Novartis Investigative Site

    Negrar, VR, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.